NEW YORK.
The modern pharmaceutical launched his draft from mRNA vaccine against VIH / page, opening the esperanza to achieve a long-awaited medical milestone.
The draft is a collaboration between Modern, the International AIDS Vaccine Initiative (IAVI) and the Bill and Melinda Gates Foundation (BMGF), reports the Official site clinicaltrials.gov.
Phase 1 clinical trials include 56 healthy HIV-negative adults to test mRNA-1644 vaccine safety and basic immune response.
This vaccine candidate is based on the same platform of MRNA that the immunizer against covid-19 developed by Moderna.
MRNA-1644 will be the first HIV mRNA vaccine to be tested in humans.
Moderna will also test another version of the candidate called mRNA-1644v2-Core.
Both have been tested for safety in non-human subjects.
The director of the US company, Stéphane Bancel, anticipated last January that Moderna would launch in search of a cutting-edge vaccine against HIV.
In the announcement, he revealed two other vaccine projects focused on seasonal flu and Nipah virus.
jrr
.
